Landscape → Immunology

Lupus Clinical Trial Landscape

Data updated: May 20, 2026

636 clinical trials tracked since 2008

Lupus is being studied across 636 clinical trials registered since 2008, with 269 programs currently active. The competitive pipeline includes 39 active Phase 3 trials, 106 active Phase 2 trials, and 156 active Phase 1 trials. Top industry sponsors include Novartis, AstraZeneca, Bristol-Myers Squibb.

269 active

636 total (since 2008)

156

Phase 1 Active

277 total

106

Phase 2 Active

281 total

Phase 3 Active

103 total

Phase 4 Active

53 total

Top Industry Sponsors

Sorted by active Active Done Failed

Novartis 10 3 4

AstraZeneca 9 9 2

Bristol-Myers Squibb 6 13 3

Roche 6 4 2

China Immunotech (Beijing) Biotechnology Co., Ltd. 6 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07355218 RECRUITING

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

EMD Serono Research & Development Institute, Inc. n=202

NCT04221477 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Hoffmann-La Roche n=271

NCT07332481 RECRUITING

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

EMD Serono Research & Development Institute, Inc. n=202

NCT07438496 RECRUITING

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Janssen Research & Development, LLC n=600

NCT05648500 ACTIVE NOT RECRUITING

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Viatris Innovation GmbH n=470

+ 98 more Phase 3 trials — see full database below

Lupus — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Novartis

AstraZeneca

Bristol-Myers Squibb

Roche

China Immunotech (Beijing) Biotechnology Co., Ltd.

Biogen

Chongqing Precision Biotech Co., Ltd

GSK

Viatris Innovation GmbH

Beijing Mabworks Biotech Co., Ltd.

Active Trials by Phase

Phase 1

156

Phase 2

106

Phase 3

Phase 4

Enrollment Size Distribution

1-50

302

51-200

177

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Novartis 10 3 4

AstraZeneca 9 9 2

Bristol-Myers Squibb 6 13 3

Roche 6 4 2

China Immunotech (Beijing) Biotechnology Co., Ltd. 6 0 0

Biogen 5 3 2

Chongqing Precision Biotech Co., Ltd 5 0 0

GSK 4 17 2

Viatris Innovation GmbH 4 2 0

Beijing Mabworks Biotech Co., Ltd. 3 0 0

Miltenyi Biomedicine GmbH 3 0 0

Sanofi 2 3 1

EMD Serono Research & Development Institute, Inc. 2 2 1

AbbVie 2 2 0

Guangdong Hengrui Pharmaceutical Co., Ltd 2 1 0

NCT07355218 RECRUITING

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

EMD Serono Research & Development Institute, Inc. n=202

NCT04221477 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Hoffmann-La Roche n=271

NCT07332481 RECRUITING

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

EMD Serono Research & Development Institute, Inc. n=202

NCT05352919 ENROLLING BY INVITATION

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Biogen n=864

NCT07438496 RECRUITING

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Janssen Research & Development, LLC n=600

NCT06475742 ENROLLING BY INVITATION

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Viatris Innovation GmbH n=680

NCT05648500 ACTIVE NOT RECRUITING

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Viatris Innovation GmbH n=470

NCT05835310 RECRUITING

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

AstraZeneca n=100

NCT06044337 ENROLLING BY INVITATION

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Biogen n=322

NCT07430306 RECRUITING

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

AstraZeneca n=245

NCT07405970 RECRUITING

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Beijing Mabworks Biotech Co., Ltd. n=316

NCT06015737 ACTIVE NOT RECRUITING

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

AstraZeneca n=306

NCT06617325 RECRUITING

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

UCB Biopharma SRL n=450

NCT04976322 ENROLLING BY INVITATION

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

UCB Biopharma SRL n=760

NCT07201129 RECRUITING

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Viatris Innovation GmbH n=300

NCT05843643 ACTIVE NOT RECRUITING

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

AbbVie n=1,014

NCT05531565 RECRUITING

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Biogen n=450

NCT04877691 ACTIVE NOT RECRUITING

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

AstraZeneca n=367

NCT04963296 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Hoffmann-La Roche n=303

NCT05672576 ACTIVE NOT RECRUITING

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Viatris Innovation GmbH n=451

NCT05126277 RECRUITING

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Novartis Pharmaceuticals n=462

NCT06133972 RECRUITING

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Novartis Pharmaceuticals n=550

NCT06711887 RECRUITING

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Novartis Pharmaceuticals n=315

NCT05624749 ACTIVE NOT RECRUITING

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Novartis Pharmaceuticals n=288

NCT05639114 ACTIVE NOT RECRUITING

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Novartis Pharmaceuticals n=436

NCT05799378 RECRUITING

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NYU Langone Health n=330

NCT05138133 ACTIVE NOT RECRUITING

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

AstraZeneca n=359

NCT04895241 ACTIVE NOT RECRUITING

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Biogen n=548

NCT04961567 ACTIVE NOT RECRUITING

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Biogen n=562

NCT05617677 ACTIVE NOT RECRUITING

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Bristol-Myers Squibb n=516

NCT05620407 ACTIVE NOT RECRUITING

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

Bristol-Myers Squibb n=513

NCT04702256 RECRUITING

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

Assistance Publique - Hôpitaux de Paris n=196

NCT04582136 ACTIVE NOT RECRUITING

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Chinese SLE Treatment And Research Group n=146

NCT06965244 NOT YET RECRUITING

Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus

Assistance Publique - Hôpitaux de Paris n=122

NCT06904729 RECRUITING

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

Guangzhou Women and Children's Medical Center n=50

NCT05458622 ACTIVE NOT RECRUITING

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

University Hospital, Brest n=25

NCT03747159 ACTIVE NOT RECRUITING

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

Leiden University Medical Center n=70

NCT06618573 RECRUITING

Safety of Administering Isoniazid to SLE Patients to Prevent TB

Universitas Padjadjaran n=60

NCT06406205 RECRUITING

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Qilu Pharmaceutical Co., Ltd. n=270

NCT05001737 COMPLETED

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Swedish Orphan Biovitrum n=33

NCT05962788 TERMINATED

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

Aurinia Pharmaceuticals Inc. n=4

NCT05288855 TERMINATED

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

Aurinia Pharmaceuticals Inc. n=9

NCT05306574 TERMINATED

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Vor Biopharma n=91

NCT06456567 WITHDRAWN

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Vor Biopharma

NCT04931563 COMPLETED

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

AstraZeneca n=277

NCT02630628 COMPLETED

Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis

The University of Hong Kong n=130

NCT01284725 COMPLETED

Weaning of Immunosuppression in Nephritis of Lupus

Assistance Publique Hopitaux De Marseille n=100

NCT00611663 COMPLETED

Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus

Assistance Publique - Hôpitaux de Paris n=47

NCT05609812 WITHDRAWN

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Vera Therapeutics, Inc.

NCT04181762 TERMINATED

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Novartis Pharmaceuticals n=275

NCT05232864 TERMINATED

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Novartis Pharmaceuticals n=31

NCT04294667 COMPLETED

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

UCB Biopharma SRL n=321

NCT03517722 TERMINATED

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Janssen Research & Development, LLC n=516

NCT03312907 COMPLETED

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

GlaxoSmithKline n=292

NCT04060888 WITHDRAWN

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Janssen Research & Development, LLC

NCT02457221 COMPLETED

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Astellas Pharma China, Inc. n=314

NCT05063513 WITHDRAWN

Autologous Stem Cell Transplantation: International Lupus Trial

European Society for Blood and Marrow Transplantation

NCT03843125 TERMINATED

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Eli Lilly and Company n=1,147

NCT04082416 COMPLETED

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

RemeGen Co., Ltd. n=335

NCT03021499 COMPLETED

Aurinia Renal Response in Active Lupus With Voclosporin

Aurinia Pharmaceuticals Inc. n=358

NCT04806113 COMPLETED

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

McGill University Health Centre/Research Institute of the McGill University Health Centre n=220

NCT03616912 TERMINATED

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Eli Lilly and Company n=830

NCT02794285 COMPLETED

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

AstraZeneca n=559

NCT02446912 COMPLETED

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

AstraZeneca n=460

NCT02446899 COMPLETED

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

AstraZeneca n=373

NCT01240694 TERMINATED

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Cephalon, Inc. n=136

NCT03597464 COMPLETED

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

Aurinia Pharmaceuticals Inc. n=216

NCT03616964 COMPLETED

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

Eli Lilly and Company n=778

NCT05326841 COMPLETED

Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .

Dr Cipto Mangunkusumo General Hospital n=60

NCT01639339 COMPLETED

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Human Genome Sciences Inc., a GSK Company n=448

NCT01714817 TERMINATED

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Bristol-Myers Squibb n=695

NCT00626197 TERMINATED

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Genentech, Inc. n=381

NCT01261793 COMPLETED

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

UCB Pharma n=791

NCT01597622 COMPLETED

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

GlaxoSmithKline n=142

NCT02119156 COMPLETED

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

GlaxoSmithKline n=80

NCT00712933 COMPLETED

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Human Genome Sciences Inc., a GSK Company n=738

NCT01345253 COMPLETED

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

GlaxoSmithKline n=709

NCT03979976 COMPLETED

Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus

Federal University of São Paulo n=37

NCT02256150 COMPLETED

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

Asahi Kasei Therapeutics Corporation n=250

NCT02504645 COMPLETED

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

ImmuPharma n=202

NCT03427151 COMPLETED

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

ImmuPharma n=62

NCT01408576 COMPLETED

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

UCB Pharma n=1,250

NCT01262365 COMPLETED

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

UCB Pharma n=793

NCT01205438 COMPLETED

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Eli Lilly and Company n=1,124

NCT02041091 TERMINATED

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Eli Lilly and Company n=226

NCT01196091 COMPLETED

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Eli Lilly and Company n=1,164

NCT01484496 COMPLETED

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Human Genome Sciences Inc., a GSK Company n=839

NCT01488708 TERMINATED

On Open-Label Study in Participants With Systemic Lupus Erythematosus

Eli Lilly and Company n=1,518

NCT01773616 TERMINATED

Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis

Imperial College London n=24

NCT01257802 TERMINATED

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Joseph Mccune n=14

NCT02514967 TERMINATED

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Anthera Pharmaceuticals n=3

NCT01395745 COMPLETED

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Anthera Pharmaceuticals n=442

NCT00724867 COMPLETED

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Human Genome Sciences Inc., a GSK Company n=268

NCT00624338 COMPLETED

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

EMD Serono n=461

NCT02074020 WITHDRAWN

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Anthera Pharmaceuticals

NCT01765842 TERMINATED

Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy

Fundación Pública Andaluza Progreso y Salud n=9

NCT01299922 WITHDRAWN

Clinical Trial Treatment in Lupus Nephritis

Hospital Universitario Fundación Alcorcón

NCT01342016 TERMINATED

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Astellas Pharma Inc n=84

NCT01015456 TERMINATED

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Chulalongkorn University n=59

NCT01551069 COMPLETED

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Sanofi n=103

NCT01288664 WITHDRAWN

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis

Sun Yat-sen University

NCT01042457 COMPLETED

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Chulalongkorn University n=24

NCT01328834 COMPLETED

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis

Sun Yat-sen University n=20

NCT06897930 RECRUITING

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

AstraZeneca

NCT06293365 ACTIVE NOT RECRUITING

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Novartis Pharmaceuticals

NCT07509892 NOT YET RECRUITING

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07570862 NOT YET RECRUITING

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

Fate Therapeutics

NCT07299422 RECRUITING

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07015983 RECRUITING

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

NCT06570798 RECRUITING

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Amgen

NCT05039619 RECRUITING

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Hoffmann-La Roche

NCT07564596 NOT YET RECRUITING

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Climb Bio, Inc.

NCT07557927 NOT YET RECRUITING

A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

Kunming Pharmaceuticals, Inc.

NCT07409181 RECRUITING

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Boehringer Ingelheim

NCT07515014 RECRUITING

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Eisai Co., Ltd.

NCT07053800 RECRUITING

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

Autolus Limited

NCT07311200 RECRUITING

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

InventisBio Co., Ltd

NCT00775476 ACTIVE NOT RECRUITING

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

State University of New York - Upstate Medical University

NCT06980805 RECRUITING

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Immunovant Sciences GmbH

NCT05268289 RECRUITING

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Novartis Pharmaceuticals

NCT07538154 NOT YET RECRUITING

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Sinocelltech Ltd.

NCT07266090 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)

Viatris Pharmaceuticals Co., Ltd.

NCT05540327 ACTIVE NOT RECRUITING

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

NCT06434363 RECRUITING

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

M.D. Anderson Cancer Center

NCT07523542 RECRUITING

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Beijing Biotech

NCT06121297 RECRUITING

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Cabaletta Bio

NCT07089121 RECRUITING

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Cartesian Therapeutics

NCT05966480 ACTIVE NOT RECRUITING

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Alumis Inc

NCT06530849 RECRUITING

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Gracell Biotechnologies (Shanghai) Co., Ltd.

NCT07260877 RECRUITING

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Ventus Therapeutics U.S., Inc.

NCT05440422 RECRUITING

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT07447986 RECRUITING

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Hangzhou Sumgen Biotech Co., Ltd.

NCT03152058 RECRUITING

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

David Ware Branch

NCT05039840 ACTIVE NOT RECRUITING

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Sanofi

NCT06038474 ACTIVE NOT RECRUITING

Descartes-08 for Patients With Systemic Lupus Erythematosus

Cartesian Therapeutics

NCT05798117 ACTIVE NOT RECRUITING

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Novartis Pharmaceuticals

NCT05538208 RECRUITING

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Children's Hospital Medical Center, Cincinnati

NCT07340463 RECRUITING

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Nanjing University School of Medicine

NCT06585514 RECRUITING

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Beijing GoBroad Hospital

NCT07348055 RECRUITING

A Study of GR1803 in Systemic Lupus Erythematosus

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

NCT06599658 RECRUITING

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT06557265 RECRUITING

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Nkarta, Inc.

NCT06947460 RECRUITING

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Beijing GoBroad Hospital

NCT06947473 RECRUITING

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Beijing GoBroad Hospital

NCT07440537 NOT YET RECRUITING

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

Beijing InnoCare Pharma Tech Co., Ltd.

NCT06839976 RECRUITING

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Children's Hospital of Philadelphia

NCT06581198 RECRUITING

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Novartis Pharmaceuticals

NCT06032923 RECRUITING

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

National Heart, Lung, and Blood Institute (NHLBI)

NCT07393451 NOT YET RECRUITING

A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis

Simcere Pharmaceutical Co., Ltd

NCT07010835 RECRUITING

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Excyte Biopharma Ltd

NCT06935474 NOT YET RECRUITING

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

AbelZeta Inc.

NCT07363460 RECRUITING

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

Haisco Pharmaceutical Group Co., Ltd.

NCT07364396 NOT YET RECRUITING

Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus

Curocell Inc.

NCT06717815 RECRUITING

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

Nanjing Immunophage Biotech Co., Ltd

NCT07328581 NOT YET RECRUITING

BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

iCell Gene Therapeutics

NCT05201469 RECRUITING

VIBRANT: VIB4920 for Active Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05796206 ACTIVE NOT RECRUITING

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Beijing Mabworks Biotech Co., Ltd.

NCT06625671 RECRUITING

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

DualityBio Inc.

NCT06182969 RECRUITING

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Ascentage Pharma Group Inc.

NCT07229742 RECRUITING

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07185269 RECRUITING

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT06189157 RECRUITING

MB-CART19.1 in Refractory SLE

Miltenyi Biomedicine GmbH

NCT07038382 RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Shanghai Henlius Biotech

NCT07225543 NOT YET RECRUITING

2-HOBA in Systemic Lupus Erythematosus

Vanderbilt University Medical Center

NCT06342960 ACTIVE NOT RECRUITING

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Kyverna Therapeutics

NCT05938725 ACTIVE NOT RECRUITING

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Kyverna Therapeutics

NCT07221565 ENROLLING BY INVITATION

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Truway Health, Inc.

NCT04179032 ACTIVE NOT RECRUITING

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

GlaxoSmithKline

NCT05732402 ACTIVE NOT RECRUITING

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Alpine Immune Sciences, Inc.

NCT05029336 RECRUITING

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Stephan Grupp MD PhD

NCT06347718 RECRUITING

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

Miltenyi Biomedicine GmbH

NCT04486118 ACTIVE NOT RECRUITING

Centrally Acting ACE Inhibition in SLE

Northwell Health

NCT04857034 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Bristol-Myers Squibb

NCT06828042 RECRUITING

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Peking University Third Hospital

NCT06559163 RECRUITING

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Zenas BioPharma (USA), LLC

NCT03673748 RECRUITING

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Red de Terapia Celular

NCT04868838 ACTIVE NOT RECRUITING

Daratumumab to Treat Active Lupus Nephritis

Mayo Clinic

NCT07044115 ACTIVE NOT RECRUITING

Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

Beijing Mabworks Biotech Co., Ltd.

NCT07041801 RECRUITING

Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

Shenzhen Beike Bio-Technology Co., Ltd.

NCT07000292 NOT YET RECRUITING

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

Shanghai Changzheng Hospital

NCT04895696 ACTIVE NOT RECRUITING

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Bristol-Myers Squibb

NCT06987565 NOT YET RECRUITING

Transcutaneous Vagus Nerve Stimulation in SLE

Northwell Health

NCT06971913 NOT YET RECRUITING

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Peking University People's Hospital

NCT06685042 RECRUITING

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT06794008 RECRUITING

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Peking University People's Hospital

NCT06261021 RECRUITING

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

Innovaderm Research Inc.

NCT06888973 ENROLLING BY INVITATION

Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

NCT06859931 NOT YET RECRUITING

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT06841042 RECRUITING

A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

Sinocelltech Ltd.

NCT06821659 NOT YET RECRUITING

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

Peking University Third Hospital

NCT06791772 NOT YET RECRUITING

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Keymed Biosciences Co.Ltd

NCT06106893 RECRUITING

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06106906 RECRUITING

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06155604 RECRUITING

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

The University of Hong Kong

NCT06428188 RECRUITING

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Essen Biotech

NCT06675422 RECRUITING

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

NCT05504187 NOT YET RECRUITING

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Kira Pharmacenticals (US), LLC.

NCT06350110 RECRUITING

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Essen Biotech

NCT06015230 ACTIVE NOT RECRUITING

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

NCT05680480 RECRUITING

A Study of Telitacicept in Lupus Nephritis

RemeGen Co., Ltd.

NCT05688696 RECRUITING

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Beijing InnoCare Pharma Tech Co., Ltd.

NCT06535412 NOT YET RECRUITING

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

NCT06356740 NOT YET RECRUITING

Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

Hospices Civils de Lyon

NCT06058078 RECRUITING

RY_SW01 Cell Injection Therapy in Active Lupus Nephritis

Jiangsu Renocell Biotech Company

NCT05508009 RECRUITING

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Alice Bertaina

NCT04736953 NOT YET RECRUITING

Sirolimus Treatment Of Patients With SLE

State University of New York - Upstate Medical University

NCT07598396 RECRUITING

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Hoffmann-La Roche

NCT03093402 COMPLETED

JBT-101 in Systemic Lupus Erythematosus (SLE)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03527472 COMPLETED

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Vanderbilt University Medical Center

NCT01649765 COMPLETED

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

GlaxoSmithKline

NCT05087628 TERMINATED

PRV-3279-2a Trial in Systemic Lupus

Provention Bio, a Sanofi Company

NCT03920267 COMPLETED

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Bristol-Myers Squibb

NCT05879718 TERMINATED

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Pfizer

NCT07096557 COMPLETED

The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus

Ain Shams University

NCT03288324 COMPLETED

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Children's Hospital Medical Center, Cincinnati

NCT04883619 WITHDRAWN

A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Janssen Research & Development, LLC

NCT05629208 TERMINATED

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Gilead Sciences

NCT02633163 COMPLETED

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Medical University of South Carolina

NCT04564339 TERMINATED

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Alexion Pharmaceuticals, Inc.

NCT05856448 COMPLETED

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Lakefront Biotherapeutics NV

NCT01351662 COMPLETED

Balancing Lupus Experiences With Stress Strategies

Medical University of South Carolina

NCT05810948 COMPLETED

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

argenx

NCT07281105 COMPLETED

EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study

Evergreen Therapeutics, Inc.

NCT04882878 COMPLETED

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Janssen Research & Development, LLC

NCT05781750 TERMINATED

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Kezar Life Sciences, Inc.

NCT05162586 COMPLETED

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

EMD Serono Research & Development Institute, Inc.

NCT05433857 COMPLETED

Probiotics in Systemic Lupus Erythematosus

Ain Shams University

NCT03393013 COMPLETED

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Kezar Life Sciences, Inc.

NCT05591222 TERMINATED

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Amgen

NCT02770170 COMPLETED

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Boehringer Ingelheim

NCT05097989 TERMINATED

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Alexion Pharmaceuticals, Inc.

NCT03656562 COMPLETED

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Novartis Pharmaceuticals

NCT02472795 COMPLETED

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Viatris Innovation GmbH

NCT03742037 COMPLETED

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Viatris Innovation GmbH

NCT03030118 COMPLETED

Study of Anti-Malarials in Incomplete Lupus Erythematosus

Milton S. Hershey Medical Center

NCT05306873 TERMINATED

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04781816 COMPLETED

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Sanofi

NCT05000216 TERMINATED

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04835441 COMPLETED

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Alpine Immune Sciences Inc, A Subsidiary of Vertex

NCT06161116 TERMINATED

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Merck Sharp & Dohme LLC

NCT04908280 COMPLETED

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

University of Rochester

NCT06419205 WITHDRAWN

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Q32 Bio Inc.

NCT05638802 COMPLETED

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Daiichi Sankyo

NCT04376827 TERMINATED

A Study of Guselkumab in Participants With Active Lupus Nephritis

Janssen Research & Development, LLC

NCT05540665 TERMINATED

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Amgen

NCT03958955 TERMINATED

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

LEO Pharma

NCT03453619 COMPLETED

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Apellis Pharmaceuticals, Inc.

NCT06153095 WITHDRAWN

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Lyell Immunopharma, Inc.

NCT05123586 TERMINATED

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Eli Lilly and Company

NCT04451772 COMPLETED

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

AbbVie

NCT04077684 COMPLETED

Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial

Peking University People's Hospital

NCT04643470 COMPLETED

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

BeiGene

NCT05714670 COMPLETED

The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis

Ain Shams University

NCT06570434 WITHDRAWN

Phase 1b/2a in SLE With Budoputug

Tenet Medicines

NCT03610516 COMPLETED

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Novartis Pharmaceuticals

NCT04058028 COMPLETED

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Amgen

NCT05430854 TERMINATED

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Amgen

NCT03845517 COMPLETED

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Pfizer

NCT02550652 COMPLETED

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Hoffmann-La Roche

NCT04925934 COMPLETED

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

Amgen

NCT01687192 COMPLETED

Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.

University Hospital, Bordeaux

NCT04680637 TERMINATED

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Amgen

NCT00779194 COMPLETED

Prospective Study of Rapamycin for the Treatment of SLE

State University of New York - Upstate Medical University

NCT04643067 COMPLETED

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

Kangpu Biopharmaceuticals, Ltd.

NCT02908100 COMPLETED

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Genentech, Inc.

NCT04433585 COMPLETED

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Nektar Therapeutics

NCT03355482 TERMINATED

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

Oklahoma Medical Research Foundation

NCT04186871 COMPLETED

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Bristol-Myers Squibb

NCT02847598 COMPLETED

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

Biogen

NCT03951259 COMPLETED

Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

RenJi Hospital

NCT05278663 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

Eisai Co., Ltd.

NCT05101447 WITHDRAWN

Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis

Children's Hospital Medical Center, Cincinnati

NCT03978520 COMPLETED

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

AbbVie

NCT05921058 COMPLETED

The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients

Universitas Sebelas Maret

NCT03161483 COMPLETED

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Celgene

NCT02962960 COMPLETED

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

AstraZeneca

NCT03252587 COMPLETED

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Bristol-Myers Squibb

NCT01135459 COMPLETED

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

Cephalon, Inc.

NCT04305197 COMPLETED

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Beijing InnoCare Pharma Tech Co., Ltd.

NCT03943147 TERMINATED

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Bristol-Myers Squibb

NCT03953261 TERMINATED

Effect of Curcumin on Systemic Lupus Erythematosus

Loma Linda University

NCT03385564 COMPLETED

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Boehringer Ingelheim

NCT01085084 COMPLETED

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Teva Branded Pharmaceutical Products R&D, Inc.

NCT05430087 COMPLETED

Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients

Saiful Anwar Hospital

NCT02677688 TERMINATED

Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)

Nantes University Hospital

NCT03371251 COMPLETED

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

Boston Pharmaceuticals

NCT01085097 COMPLETED

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Teva Branded Pharmaceutical Products R&D, Inc.

NCT02270957 COMPLETED

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

Oklahoma Medical Research Foundation

NCT02547922 COMPLETED

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

AstraZeneca

NCT02338999 COMPLETED

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT03866317 WITHDRAWN

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Massachusetts General Hospital

NCT01988506 COMPLETED

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Assistance Publique - Hôpitaux de Paris

NCT02804763 COMPLETED

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

UCB Biopharma S.P.R.L.

NCT02141672 COMPLETED

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

Aurinia Pharmaceuticals Inc.

NCT02429934 TERMINATED

Abatacept for SLE Arthritis (IM101-330)

University of California, Los Angeles

NCT02975336 TERMINATED

A Phase II Study of M2951 in SLE

EMD Serono Research & Development Institute, Inc.

NCT02949973 COMPLETED

Aurinia Early Urinary Protein Reduction Predicts Response

Aurinia Pharmaceuticals Inc.

NCT02660944 COMPLETED

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Resolve Therapeutics

NCT00708916 COMPLETED

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

NYU Langone Health

NCT01379573 COMPLETED

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NYU Langone Health

NCT04184258 COMPLETED

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

NCT03407482 TERMINATED

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Genentech, Inc.

NCT02260934 COMPLETED

Rituximab and Belimumab for Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03312335 COMPLETED

Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus

Onur Boyman, MD

NCT01946880 TERMINATED

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01300208 COMPLETED

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Amgen

NCT03134222 COMPLETED

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Gilead Sciences

NCT03285711 COMPLETED

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Gilead Sciences

NCT02665364 TERMINATED

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

Neovacs

NCT02349061 COMPLETED

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Janssen Research & Development, LLC

NCT02185040 COMPLETED

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Celgene

NCT02885610 COMPLETED

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

RemeGen Co., Ltd.

NCT02917265 TERMINATED

Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus

Aikaterini Thanou

NCT02066311 TERMINATED

Nelfinavir in Systemic Lupus Erythematosus

Northwell Health

NCT02554019 COMPLETED

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

Biotest

NCT02418273 WITHDRAWN

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Indiana University

NCT02102594 TERMINATED

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

Charite University, Berlin, Germany

NCT01466725 TERMINATED

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Celgene

NCT01582880 COMPLETED

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

Joseph B. Ciolino, MD

NCT02265744 COMPLETED

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Bristol-Myers Squibb

NCT02080195 TERMINATED

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02725515 COMPLETED

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Xencor, Inc.

NCT01753193 COMPLETED

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

MedImmune LLC

NCT01058343 COMPLETED

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Neovacs

NCT02070978 TERMINATED

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

EMD Serono

NCT01559090 COMPLETED

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

AstraZeneca

NCT02955615 COMPLETED

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Iltoo Pharma

NCT02284984 COMPLETED

Synergetic B-cell Immodulation in SLE

Leiden University Medical Center

NCT02656082 COMPLETED

Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

University of Leeds

NCT02437890 COMPLETED

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

Ablynx, a Sanofi company

NCT02708095 COMPLETED

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Eli Lilly and Company

NCT01031836 COMPLETED

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

AstraZeneca

NCT02533570 TERMINATED

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Seagen Inc.

NCT02711813 TERMINATED

TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment

Theramab LLC

NCT01283139 COMPLETED

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

MedImmune LLC

NCT02124798 COMPLETED

A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector

GlaxoSmithKline

NCT01972568 COMPLETED

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

EMD Serono

NCT01405196 COMPLETED

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

Pfizer

NCT01911169 COMPLETED

Vitamin D to Improve Endothelial Function in SLE

Medical University of South Carolina

NCT02320357 COMPLETED

Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous

University Hospital, Bordeaux

NCT03200002 COMPLETED

Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Chitwan Medical College

NCT00710021 COMPLETED

Vitamin D3 in Systemic Lupus Erythematosus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01777256 TERMINATED

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

GlaxoSmithKline

NCT01294774 COMPLETED

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Novartis Pharmaceuticals

NCT02949349 COMPLETED

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Genovate Biotechnology Co., Ltd.,

NCT01838694 COMPLETED

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

Invion, Inc.

NCT01930890 TERMINATED

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Biogen

NCT01499355 TERMINATED

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Biogen

NCT00979654 COMPLETED

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

MedImmune LLC

NCT01438489 COMPLETED

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

MedImmune LLC

NCT02875691 COMPLETED

Effect of Green Tea on Treatment of Lupus

Ahvaz Jundishapur University of Medical Sciences

NCT00962832 COMPLETED

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Genentech, Inc.

NCT00657189 COMPLETED

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

MedImmune LLC

NCT01597050 COMPLETED

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Rigel Pharmaceuticals

NCT01407679 TERMINATED

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

University Hospital Muenster

NCT01534403 COMPLETED

Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

UCB Pharma

NCT02756546 COMPLETED

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Cairo University

NCT01273389 COMPLETED

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Janssen Research & Development, LLC

NCT00774852 COMPLETED

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01738360 TERMINATED

Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Nantes University Hospital

NCT01709474 TERMINATED

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00997100 COMPLETED

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

Active Biotech AB

NCT01170585 COMPLETED

A Trial of Rosuvastatin in Systemic Lupus Erythematosus

Imperial College London

NCT00987831 COMPLETED

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)

Oklahoma Medical Research Foundation

NCT01162681 COMPLETED

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Anthera Pharmaceuticals

NCT01352988 COMPLETED

Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

University Hospital Muenster

NCT01305746 COMPLETED

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Anthera Pharmaceuticals

NCT01449071 COMPLETED

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

UCB Pharma

NCT02021513 COMPLETED

Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus

University of Texas Southwestern Medical Center

NCT01498406 TERMINATED

Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

Emory University

NCT01440231 WITHDRAWN

Atacicept Demonstrating Dose RESponSe

EMD Serono

NCT00732940 TERMINATED

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Human Genome Sciences Inc.

NCT00447265 TERMINATED

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01702038 WITHDRAWN

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00660881 COMPLETED

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

UCB Pharma

NCT00752999 WITHDRAWN

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

Rigel Pharmaceuticals

NCT00624351 COMPLETED

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

UCB Pharma

NCT01072734 COMPLETED

Auto-immunity in Lupus Patients After Influenza Vaccine

Assistance Publique - Hôpitaux de Paris

NCT07262983 RECRUITING

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03816345 RECRUITING

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

NCT06977724 RECRUITING

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

AbbVie

NCT05835986 RECRUITING

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Hoffmann-La Roche

NCT07085676 RECRUITING

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Polina Stepensky

NCT05869955 RECRUITING

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

NCT07363590 RECRUITING

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Merck Sharp & Dohme LLC

NCT06308978 RECRUITING

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Fate Therapeutics

NCT06576271 RECRUITING

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

GlaxoSmithKline

NCT06801119 RECRUITING

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

Shenzhen MagicRNA Biotechnology Co., Ltd

NCT06916806 RECRUITING

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

AstraZeneca

NCT06984341 NOT YET RECRUITING

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

Genentech, Inc.

NCT07544225 NOT YET RECRUITING

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

Gustave Roussy, Cancer Campus, Grand Paris

NCT07219563 RECRUITING

Alnuctamab for Refractory SLE (LATTE Study)

Icahn School of Medicine at Mount Sinai

NCT07276958 RECRUITING

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Eli Lilly and Company

NCT07523282 NOT YET RECRUITING

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Shenzhen MagicRNA Biotechnology Co., Ltd

NCT07323173 RECRUITING

A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

Nanjing Leads Biolabs Co.,Ltd

NCT06975787 RECRUITING

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Regeneron Pharmaceuticals

NCT07516639 NOT YET RECRUITING

First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

SUNHO（China）BioPharmaceutical CO., Ltd.

NCT07085104 RECRUITING

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Allogene Therapeutics

NCT07038447 ENROLLING BY INVITATION

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Kite, A Gilead Company

NCT07512947 NOT YET RECRUITING

Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06013995 RECRUITING

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Bristol-Myers Squibb

NCT06917742 RECRUITING

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Capstan Therapeutics

NCT07011043 RECRUITING

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Climb Bio, Inc.

NCT07491900 RECRUITING

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Hinge Bio

NCT07490275 NOT YET RECRUITING

Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT06335979 RECRUITING

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Novartis Pharmaceuticals

NCT06647069 RECRUITING

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Sanofi

NCT07483346 NOT YET RECRUITING

IASO-782 in Systemic Lupus Erythematosus

Shanghai IASO Biotechnology Co., Ltd

NCT06613360 RECRUITING

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Cullinan Therapeutics Inc.

NCT06375993 ENROLLING BY INVITATION

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

Adicet Therapeutics

NCT07371468 RECRUITING

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

GlaxoSmithKline

NCT06822881 RECRUITING

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Beijing GoBroad Hospital

NCT06144710 ACTIVE NOT RECRUITING

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Hangzhou Sumgen Biotech Co., Ltd.

NCT07455578 NOT YET RECRUITING

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Seismic Therapeutic AU Pty Ltd

NCT07236762 RECRUITING

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT07123519 RECRUITING

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT07444307 RECRUITING

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Hangzhou Qihan Biotech Co., Ltd.

NCT07104721 RECRUITING

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT07236801 RECRUITING

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT06333483 RECRUITING

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

Autolus Limited

NCT07439029 NOT YET RECRUITING

YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases

Children's Hospital of Fudan University

NCT07432334 NOT YET RECRUITING

CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

Vinmec Research Institute of Stem Cell and Gene Technology

NCT06152172 ACTIVE NOT RECRUITING

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

David Porter

NCT07201558 RECRUITING

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

AstraZeneca

NCT07413341 RECRUITING

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Therorna

NCT07408908 NOT YET RECRUITING

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

Xiamen Amoytop Biotech Co., Ltd.

NCT07403097 RECRUITING

Study of CD19 CAR-T Therapy for Refractory SLE

Chongqing Precision Biotech Co., Ltd

NCT06222853 ACTIVE NOT RECRUITING

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

The Children's Hospital of Zhejiang University School of Medicine

NCT07318259 RECRUITING

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Chongqing Precision Biotech Co., Ltd

NCT07305116 RECRUITING

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

The Children's Hospital of Zhejiang University School of Medicine

NCT07331272 RECRUITING

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Nanjing Legend Biotech Co.

NCT07306585 NOT YET RECRUITING

The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

HC Biopharma Inc.

NCT07109986 RECRUITING

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

Nanjing IASO Biotechnology Co., Ltd.

NCT07358988 NOT YET RECRUITING

KN5501 Cell Injection for Refractory SLE(CLEAR)

Ruitherapeutics Co., LTD

NCT07361094 RECRUITING

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Beijing Boren Hospital

NCT07315087 RECRUITING

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT07331467 RECRUITING

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Chongqing Precision Biotech Co., Ltd

NCT06255028 ACTIVE NOT RECRUITING

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Century Therapeutics, Inc.

NCT06064929 ACTIVE NOT RECRUITING

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

HI-Bio, A Biogen Company

NCT06892145 RECRUITING

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Chongqing Precision Biotech Co., Ltd

NCT06925542 RECRUITING

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

CRISPR Therapeutics

NCT06465147 RECRUITING

REACT-01: Reversing Autoimmunity Through Cell Therapy

Seattle Children's Hospital

NCT06265220 ACTIVE NOT RECRUITING

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Artiva Biotherapeutics, Inc.

NCT06789107 RECRUITING

Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus

Mao Jianhua

NCT06294236 ACTIVE NOT RECRUITING

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Sana Biotechnology

NCT07031713 RECRUITING

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT07233642 RECRUITING

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

The Children's Hospital of Zhejiang University School of Medicine

NCT07215663 RECRUITING

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Candid Therapeutics

NCT06544330 ACTIVE NOT RECRUITING

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Synthekine

NCT06941129 RECRUITING

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT05411016 ACTIVE NOT RECRUITING

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Kyowa Kirin Co., Ltd.

NCT06799520 RECRUITING

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT06400537 RECRUITING

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT07177911 RECRUITING

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

CytoCares Inc

NCT06737380 RECRUITING

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

LiveKidney.Bio

NCT07136389 RECRUITING

Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Biocad

NCT06249438 RECRUITING

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

RenJi Hospital

NCT06978647 RECRUITING

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT06881290 RECRUITING

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Chinese SLE Treatment And Research Group

NCT06857214 RECRUITING

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

Sichuan Baili Pharmaceutical Co., Ltd.

NCT06285279 RECRUITING

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Nanjing University School of Medicine

NCT07001839 NOT YET RECRUITING

A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus

Qilu Pharmaceutical Co., Ltd.

NCT06340750 RECRUITING

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

Luminary Therapeutics

NCT06676631 RECRUITING

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Guangdong Provincial People's Hospital

NCT06710717 RECRUITING

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

National University of Malaysia

NCT06421701 RECRUITING

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT06980597 RECRUITING

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Beijing GoBroad Hospital

NCT06978738 NOT YET RECRUITING

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Changzhou No.2 People's Hospital

NCT06943937 RECRUITING

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT06945068 NOT YET RECRUITING

An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06934447 RECRUITING

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

The Children's Hospital of Zhejiang University School of Medicine

NCT06657703 RECRUITING

Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

HC Biopharma Inc.

NCT05018858 RECRUITING

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus

The Foundation for Orthopaedics and Regenerative Medicine

NCT06349343 RECRUITING

CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06852573 NOT YET RECRUITING

Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus

Beijing Immunochina Medical Science & Technology Co., Ltd.

NCT05866861 ACTIVE NOT RECRUITING

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Cugene Inc.

NCT06708845 NOT YET RECRUITING

US Zamto-cel Autoimmune Diseases

Miltenyi Biomedicine GmbH

NCT06694298 NOT YET RECRUITING

A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NCT06691152 RECRUITING

Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

The Children's Hospital of Zhejiang University School of Medicine

NCT06581562 RECRUITING

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

IRIS Research and Development, LLC

NCT06567080 NOT YET RECRUITING

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

RenJi Hospital

NCT06468683 NOT YET RECRUITING

F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

Shanghai Simnova Biotechnology Co.,Ltd.

NCT06373991 NOT YET RECRUITING

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

EdiGene Inc.

NCT06340490 NOT YET RECRUITING

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

Guangdong Ruishun Biotech Co., Ltd

NCT06316076 RECRUITING

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

RenJi Hospital

NCT06297408 NOT YET RECRUITING

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

Shanghai Ming Ju Biotechnology Co., Ltd.

NCT04976465 RECRUITING

Treatment and Clinical Outcomes Among SLE Patients in Pregnancy

Qilu Hospital of Shandong University

NCT06056921 RECRUITING

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Chongqing Precision Biotech Co., Ltd

NCT06518668 SUSPENDED

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Columbia University

NCT07237659 COMPLETED

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

Neutrolis

NCT06150651 COMPLETED

Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.

Chulalongkorn University

NCT05687526 COMPLETED

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

RemeGen Co., Ltd.

NCT06913608 WITHDRAWN

A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

Calibr, a division of Scripps Research

NCT06955598 COMPLETED

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT05917288 COMPLETED

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

GlaxoSmithKline

NCT06188507 SUSPENDED

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

GlaxoSmithKline

NCT06752876 WITHDRAWN

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Caribou Biosciences, Inc.

NCT05048238 COMPLETED

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05155345 COMPLETED

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Hoffmann-La Roche

NCT06429800 WITHDRAWN

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Atara Biotherapeutics

NCT04128579 COMPLETED

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

Equillium

NCT06377228 WITHDRAWN

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

Takeda

NCT06238531 WITHDRAWN

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT05328557 COMPLETED

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Cugene Inc.

NCT06041568 TERMINATED

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

IGM Biosciences, Inc.

NCT02609789 COMPLETED

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Janssen Research & Development, LLC

NCT06411639 WITHDRAWN

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Novartis Pharmaceuticals

NCT02780674 COMPLETED

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Amgen

NCT03817424 COMPLETED

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Amgen

NCT05203419 TERMINATED

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Novartis Pharmaceuticals

NCT05780515 COMPLETED

A Study of ANX009 in Adult Participants With Lupus Nephritis

Annexon, Inc.

NCT02618967 COMPLETED

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Amgen

NCT05140824 TERMINATED

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

TJ Biopharma Co., Ltd.

NCT04809623 TERMINATED

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Gilead Sciences

NCT03724916 COMPLETED

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Millennium Pharmaceuticals, Inc.

NCT04647708 COMPLETED

Study of M5049 in CLE and SLE Participants

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

NCT05247203 COMPLETED

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

RemeGen Co., Ltd.

NCT03556007 COMPLETED

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

Nektar Therapeutics

NCT03334851 COMPLETED

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Pfizer

NCT05984251 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

Amgen

NCT03451422 COMPLETED

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Amgen

NCT04493541 COMPLETED

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Bristol-Myers Squibb

NCT05203692 COMPLETED

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Daiichi Sankyo

NCT03656627 TERMINATED

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Alliance Foundation Trials, LLC.

NCT02106897 COMPLETED

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Biogen

NCT05001698 COMPLETED

Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)

AstraZeneca

NCT01716312 COMPLETED

Omalizumab for Lupus

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT03618056 COMPLETED

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03771885 WITHDRAWN

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Boehringer Ingelheim

NCT04700267 TERMINATED

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

Galapagos NV

NCT01953835 COMPLETED

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

GlaxoSmithKline

NCT01541670 TERMINATED

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

Baxalta now part of Shire

NCT02927457 COMPLETED

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

GlaxoSmithKline

NCT03933943 COMPLETED

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Eli Lilly and Company

NCT04065932 COMPLETED

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Bristol-Myers Squibb

NCT04136145 COMPLETED

Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects

GlaxoSmithKline

NCT02880852 COMPLETED

Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus

GlaxoSmithKline

NCT04318600 COMPLETED

Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis

Yan'an Affiliated Hospital of Kunming Medical University

NCT03262727 COMPLETED

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Bristol-Myers Squibb

NCT03402087 COMPLETED

A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

Bristol-Myers Squibb

NCT03254784 COMPLETED

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Bristol-Myers Squibb

NCT03949426 COMPLETED

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Kangpu Biopharmaceuticals, Ltd.

NCT03541564 COMPLETED

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Bristol-Myers Squibb

NCT03174587 COMPLETED

Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis

Corestemchemon, Inc.

NCT02428309 TERMINATED

Autologous Polyclonal Tregs for Lupus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03189017 COMPLETED

A Phase I Study of ICP-022 in Healthy Subjects

Innocare Pharma Australia Pty Ltd

NCT03171194 COMPLETED

Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

Medical University of South Carolina

NCT02176486 TERMINATED

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Takeda

NCT00714116 COMPLETED

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Pfizer

NCT01741012 COMPLETED

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Wayne State University

NCT02535689 COMPLETED

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT01687309 COMPLETED

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender

GlaxoSmithKline

NCT02920424 WITHDRAWN

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Janssen Research & Development, LLC

NCT01686555 COMPLETED

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

AbbVie (prior sponsor, Abbott)

NCT02537028 COMPLETED

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

EMD Serono Research & Development Institute, Inc.

NCT02307643 COMPLETED

Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

Tanabe Pharma Corporation

NCT01516450 COMPLETED

Japanese phase1 Study of Belimumab (IV vs SC)

GlaxoSmithKline

NCT01381536 COMPLETED

Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)

GlaxoSmithKline

NCT01894360 COMPLETED

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

GlaxoSmithKline

NCT02829541 COMPLETED

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Biogen

NCT02741362 TERMINATED

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

Arkansas Heart Hospital

NCT02151409 COMPLETED

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Novo Nordisk A/S

NCT01683695 COMPLETED

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Amgen

NCT02331810 WITHDRAWN

Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients

Sanofi

NCT02321709 COMPLETED

Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients

Sanofi

NCT02483624 TERMINATED

3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus

Northwell Health

NCT02194400 COMPLETED

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Resolve Therapeutics

NCT01764594 COMPLETED

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

UCB Pharma

NCT02306629 COMPLETED

Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood

UCB Biopharma S.P.R.L.

NCT01164917 TERMINATED

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Amgen

NCT00818948 COMPLETED

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Amgen

NCT01127321 TERMINATED

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

MedImmune LLC

NCT01018238 WITHDRAWN

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Novo Nordisk A/S

NCT01689025 TERMINATED

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Novo Nordisk A/S

NCT01470313 TERMINATED

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Pfizer

NCT01389895 TERMINATED

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Amgen

NCT01369628 TERMINATED

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

EMD Serono

NCT01474720 COMPLETED

Zostavax in Systemic Lupus Erythematosus

Oklahoma Medical Research Foundation

NCT00705367 COMPLETED

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

Bristol-Myers Squibb

NCT00774943 COMPLETED

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Amgen

NCT00976729 COMPLETED

NOX-E36 First-in-Human (FIH) Study

TME Pharma AG

NCT01093911 COMPLETED

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

UCB Pharma

NCT00960362 COMPLETED

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

Argos Therapeutics

NCT06594068 RECRUITING

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

AstraZeneca

NCT05879419 ACTIVE NOT RECRUITING

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

University of Sao Paulo General Hospital

NCT07323524 NOT YET RECRUITING

Dapagliflozin in Active Lupus Nephritis

Brigham and Women's Hospital

NCT07087912 RECRUITING

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

University of Sao Paulo General Hospital

NCT06875960 RECRUITING

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Bristol-Myers Squibb

NCT07381465 NOT YET RECRUITING

Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus

Chinese SLE Treatment And Research Group

NCT07077486 RECRUITING

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

Tongji Hospital

NCT05559671 RECRUITING

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NYU Langone Health

NCT06411249 RECRUITING

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

GlaxoSmithKline

NCT07225387 RECRUITING

Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

NephroNet, Inc.

NCT07035834 NOT YET RECRUITING

SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis

Federico II University

NCT06763783 ENROLLING BY INVITATION

Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

Region Skane

NCT06677801 ACTIVE NOT RECRUITING

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT05916781 RECRUITING

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Chinese SLE Treatment And Research Group

NCT03543839 RECRUITING

Trial of Belimumab in Early Lupus

Northwell Health

NCT05207358 RECRUITING

Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

Institutul Clinic Fundeni

NCT04908865 COMPLETED

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

GlaxoSmithKline

NCT04515719 COMPLETED

Efficacy and Safety of Belimumab in SLE Patients

RenJi Hospital

NCT05748925 COMPLETED

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Mansoura University

NCT02226341 TERMINATED

ACTHar in the Treatment of Lupus Nephritis

Columbia University

NCT01316133 TERMINATED

A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients

Astellas Pharma Korea, Inc.

NCT05704088 COMPLETED

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

Mansoura University

NCT01705977 COMPLETED

Belimumab Assessment of Safety in SLE

GlaxoSmithKline

NCT03762824 COMPLETED

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease

Region Skane

NCT04956484 COMPLETED

Belimumab In Early Systemic Lupus Erythematosus

Peking Union Medical College Hospital

NCT04424602 COMPLETED

Comparison between2 Drugs in Lupus Nephritis

Al-Azhar University

NCT03122431 COMPLETED

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

University of Sao Paulo General Hospital

NCT01632241 COMPLETED

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

Human Genome Sciences Inc., a GSK Company

NCT03859570 WITHDRAWN

Pentoxifylline in Lupus Nephritis

MetroHealth Medical Center

NCT03920059 TERMINATED

Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis

Chulalongkorn University

NCT02953821 COMPLETED

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Mallinckrodt

NCT03098823 COMPLETED

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

Ampel BioSolutions, LLC

NCT01753401 COMPLETED

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

Mallinckrodt

NCT04146220 COMPLETED

Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

NCT02741960 COMPLETED

The Effect of Metformin on Reducing Lupus Flares

RenJi Hospital

NCT02779153 WITHDRAWN

Acthar SLE (Systemic Lupus Erythematosus)

NYU Langone Health

NCT02477150 COMPLETED

Safety and Immunogenicity of a Zoster Vaccine in SLE

Tuen Mun Hospital

NCT03540823 COMPLETED

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

University of Sao Paulo General Hospital

NCT01597492 COMPLETED

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Human Genome Sciences Inc., a GSK Company

NCT01926054 WITHDRAWN

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

Ohio State University

NCT00815282 COMPLETED

Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease

N.M. Wulffraat

NCT02645565 COMPLETED

Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis

Jawaharlal Institute of Postgraduate Medical Education & Research

NCT00828178 COMPLETED

Efficacy of Fish Oil in Lupus Patients

Michelle Petri M.D.,MPH

NCT01112215 COMPLETED

Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations

Hospital Universitari Vall d'Hebron Research Institute

NCT01359826 WITHDRAWN

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

Loma Linda University

NCT01276782 WITHDRAWN

Levothyroxine in Pregnant SLE Patients

Johns Hopkins University

NCT00508898 WITHDRAWN

The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria

Chinese University of Hong Kong

NCT01203709 COMPLETED

Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis

Tuen Mun Hospital

NCT01769937 COMPLETED

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Fiechtner, Justus J., M.D., P.C.

NCT01206569 COMPLETED

Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis

Chinese University of Hong Kong

NCT01169857 WITHDRAWN

Velcade for Proliferative Lupus Nephritis

The Rogosin Institute

NCT00911521 COMPLETED

Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

Tuen Mun Hospital

NCT01408199 COMPLETED

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

Hospital Universitari Vall d'Hebron Research Institute

Full Lupus Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only